Information Provided By: 
Fly News Breaks for May 30, 2019
GHDX
May 30, 2019 | 07:45 EDT
Deutsche Bank analyst Dan Leonard lowered his price target for Genomic Health to $55 from $80 to reflect his view that the company's core U.S. invasive breast cancer-testing franchise is maturing, while its efforts to deliver an "encore to its success in breast could remain slow to take root." The analyst keeps a Hold rating on the shares.
News For GHDX From the Last 2 Days
There are no results for your query GHDX
